These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 9034987

  • 1. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA.
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [Abstract] [Full Text] [Related]

  • 2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA, El-Gendi HI, Ahmed HH.
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [Abstract] [Full Text] [Related]

  • 3. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 4. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
    Muzaffer MA, Dayer JM, Feldman BM, Pruzanski W, Roux-Lombard P, Schneider R, Laxer RM, Silverman ED.
    J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
    [Abstract] [Full Text] [Related]

  • 5. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications.
    Gattorno M, Picco P, Barbano G, Stalla F, Sormani MP, Buoncompagni A, Gusmano R, Borrone C, Pistoia V.
    J Rheumatol; 1998 Feb; 25(2):361-5. PubMed ID: 9489835
    [Abstract] [Full Text] [Related]

  • 6. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K.
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP, Liljeström M, Laiho K, Tiitinen S, Kaarela K, Hurme M.
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J.
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [Abstract] [Full Text] [Related]

  • 10. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.
    Anticancer Res; 2001 Sep; 21(4B):3053-9. PubMed ID: 11712810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T, Gladalska A, Stepień H.
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [Abstract] [Full Text] [Related]

  • 13. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
    Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P.
    J Immunol; 1995 Jan 15; 154(2):882-92. PubMed ID: 7814891
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jan 15; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis.
    Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerne PA.
    J Rheumatol; 1993 May 15; 20(5):815-21. PubMed ID: 8336307
    [Abstract] [Full Text] [Related]

  • 20. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T, Fierz W, Stoll T, Villiger PM.
    J Rheumatol; 2003 Oct 15; 30(10):2133-9. PubMed ID: 14528506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.